Cargando…
User preference for a portable syringe pump for iloprost infusion
PURPOSE: Administration of intravenous iloprost – a first-line European League Against Rheumatism (EULAR)-recommended choice for the treatment of scleroderma (SSc)-related digital vasculopathy – requires repeated treatment cycles of 6 hours per day in a hospital setting. During the infusion, patient...
Autores principales: | Laria, Antonella, Lurati, Alfredo Maria, Re, Katia Angela, Marrazza, Maria Grazia, Mazzocchi, Daniela, Farina, Alberto, Scarpellini, Magda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447001/ https://www.ncbi.nlm.nih.gov/pubmed/26056502 http://dx.doi.org/10.2147/PROM.S81473 |
Ejemplares similares
-
The macrophages in rheumatic diseases
por: Laria, Antonella, et al.
Publicado: (2016) -
Improvement of HbA1c in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis Treated with bDMARDs
por: Lurati, Alfredomaria, et al.
Publicado: (2021) -
Organizational Impact of the Introduction of a New Portable Syringe Pump for Iloprost Therapy in Italian Hospital Settings
por: Restelli, Umberto, et al.
Publicado: (2015) -
Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review
por: Laria, Antonella, et al.
Publicado: (2022) -
Color duplex ultrasonography findings of temporal arteries in a case of giant cell arteritis: role in diagnosis and follow-up
por: Laria, Antonella, et al.
Publicado: (2017)